Santen Pharmaceutical Co., Ltd.
【Santen Pharmaceutical】2026 Financial Results｜Sales of 291.6 billion yen (△2.8%)
Santen Pharmaceutical recorded sales of 291.6 billion yen (YoY △2.8%) for the fiscal year ending March 2026, with core operating profit of 55.1 billion yen (△7.1%). Net income attributable to owners of the parent was 37.6 billion yen (+4.8%), and dividends are scheduled to increase to 38 yen annually. The company anticipates continued revenue growth and profit expansion next term, focusing on expanding overseas operations.
Key Figures
- Sales Revenue: 291.6 billion yen (△2.8%)
- Net Income Attributable to Owners of the Parent: 37.6 billion yen (+4.8%)
- Annual Dividends: 38 yen (scheduled increase)
AI要約
Performance Overview
For the fiscal year ending March 2026, Santen Pharmaceutical achieved sales of 291.6 billion yen (△2.8%) and core operating profit of 55.1 billion yen (△7.1%), showing slight declines. However, net income increased to 37.6 billion yen (+4.8%) due to expansion of flagship products and steady growth in overseas markets. The company plans to increase dividends to 38 yen and aims for continued revenue and profit growth next year. Strategic initiatives focus on strengthening domestic and international business operations.
Impact on Shareholders and Future Outlook
Dividends are scheduled to increase to 38 yen annually, reflecting a focus on shareholder returns. For the next term, sales are expected to reach approximately 311.0 billion yen (+6.6%), with core operating profit of 59.0 billion yen (+7.0%), indicating ongoing revenue and profit growth. The company will remain vigilant to exchange rate fluctuations and market conditions, advancing proactive business investments and efficiency measures to sustain growth.
Santen Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
